-
EP3528844
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3528844
| EP3528844 - COMBINATION THERAPY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 02.10.2020 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 26.07.2019 | ||
| Former | The international publication has been made Status updated on 28.04.2018 | ||
| Former | unknown Status updated on 24.11.2017 | Most recent event Tooltip | 02.10.2020 | Application deemed to be withdrawn | published on 04.11.2020 [2020/45] | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2019/35] | Inventor(s) | 01 /
MERGOTT, Dustin James c/o Eli Lilly and Company P.O. Box 6288 Indianapolisi, Indiana 46206-6288 / US | 02 /
WILLIS, Brian Andrew c/o Eli Lilly and Company P.O. Box 6288 Indianapolisi, Indiana 46206-6288 / US | [2019/35] | Representative(s) | Bassinder, Emma Marie Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2019/35] | Bassinder, Emma Marie Eli Lilly and Company Limited European Patent Operations Erl Wood Manor Sunninghill Road Windlesham, Surrey GU20 6PH / GB | Application number, filing date | 17797795.6 | 13.10.2017 | [2019/35] | WO2017US56451 | Priority number, date | US201662410997P | 21.10.2016 Original published format: US 201662410997 P | [2019/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018075339 | Date: | 26.04.2018 | Language: | EN | [2018/17] | Type: | A1 Application with search report | No.: | EP3528844 | Date: | 28.08.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.04.2018 takes the place of the publication of the European patent application. | [2019/35] | Search report(s) | International search report - published on: | EP | 26.04.2018 | Classification | IPC: | A61K39/395, C07K16/18, A61K39/00, A61K31/166, A61K31/541, A61K31/542, A61P25/28, C07D513/04 | [2019/35] | CPC: |
A61K31/542 (EP,US);
A61K39/3955 (EP,KR,US);
A61K31/166 (EP,US);
A61K31/541 (EP,US);
A61K31/546 (KR);
A61K39/395 (EP,US);
A61P25/28 (EP,KR,US);
C07D513/04 (EP,US);
C07K16/18 (EP,KR,US);
A61K2300/00 (KR)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/35] | Title | German: | KOMBINATIONSTHERAPIE | [2019/35] | English: | COMBINATION THERAPY | [2019/35] | French: | POLYTHÉRAPIE | [2019/35] | Entry into regional phase | 21.05.2019 | National basic fee paid | 21.05.2019 | Designation fee(s) paid | 21.05.2019 | Examination fee paid | Examination procedure | 17.05.2019 | Amendment by applicant (claims and/or description) | 21.05.2019 | Examination requested [2019/35] | 21.05.2019 | Date on which the examining division has become responsible | 03.01.2020 | Loss of particular rights, legal effect: Claims | 20.01.2020 | Despatch of communication of loss of particular rights: Claims {1} | 03.06.2020 | Application deemed to be withdrawn, date of legal effect [2020/45] | 30.06.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2020/45] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.10.2019 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2012021469 (LILLY CO ELI [US], et al) [Y] 1-32 * abstract, p. 1 line 27 - p. 7 line 11, examples 1-7 and claims *; | [Y]WO2012098213 (EISAI R&D MAN CO LTD [JP], et al) [Y] 1-32 * abstract, p. 19 line 8 - p. 21 line 3, p. 91 line 15 - p. 93 line 4, Table 5 and claims *; | [AP]WO2016176118 (LILLY CO ELI [US]) [AP] 1-32 * the whole document *; | [Y] - H. JACOBSEN ET AL, "Combined Treatment with a BACE Inhibitor and Anti-A Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice", JOURNAL OF NEUROSCIENCE, US, (20140827), vol. 34, no. 35, doi:10.1523/JNEUROSCI.1405-14.2014, ISSN 0270-6474, pages 11621 - 11630, XP055370311 [Y] 1-32 * abstract, p. 11622 the paragraph bridging the left- tothe right-hand column, p. 11624 the paragraph bridging the left- to the right-hand column - p. 11 627 left-hand column last line, Fig. 3-6 * DOI: http://dx.doi.org/10.1523/JNEUROSCI.1405-14.2014 | [A] - Fré Dé Rique Bard ET AL, "Epitope and isotype specificities of antibodies to ?-amyloid peptide for protection against Alzheimer's disease-like neuropathology", doi:10.1073/pnas.0436286100, (20020101), URL: http://www.pnas.org/content/100/4/2023.full.pdf, XP055286112 [A] 1-32 * abstract, p. 2023 right-hand column second full paragraph, p. 2026 left-hand column last 5 lines - p. 2028 left-hand column line 8, Table 1 and fig. 3 and 4 * DOI: http://dx.doi.org/10.1073/pnas.0436286100 | [A] - STEVEN MOORE ET AL, "APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons", CELL REPORTS, US, (20150501), vol. 11, no. 5, doi:10.1016/j.celrep.2015.03.068, ISSN 2211-1247, pages 689 - 696, XP055434500 [A] 1-32 * the whole document * DOI: http://dx.doi.org/10.1016/j.celrep.2015.03.068 | [A] - NAOMI MAMADA ET AL, "Amyloid [beta]-protein oligomers upregulate the [beta]-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons", MOLECULAR BRAIN, (20151109), vol. 8, no. 1, doi:10.1186/s13041-015-0163-5, XP055434504 [A] 1-32 * the whole document * DOI: http://dx.doi.org/10.1186/s13041-015-0163-5 | by applicant | US8158620 | US8278334 | US8338407 | US8679498 | WO2016043997 | - KABAT et al., Ann. NY Acad. Sci., (19710000), vol. 190, pages 382 - 93 | - NORTH et al., "A New Clustering of Antibody CDR Loop Conformations", Journal of Molecular Biology, (20110000), vol. 406, doi:doi:10.1016/j.jmb.2010.10.030, pages 228 - 256, XP028129711 DOI: http://dx.doi.org/10.1016/j.jmb.2010.10.030 | - JACS, (19990000), vol. 121, page 8649 | - "The United States Pharmacopeia #23", National Formulary #18, (19950000), pages 1843 - 1844 | - VASSAR et al., Science, (19990000), vol. 286, pages 735 - 742 | - YANG, J. Neurochemistry, (20040000), vol. 91, no. 6, pages 1249 - 59 | - VASSER et al., Science, (19990000), vol. 286, pages 735 - 741 | - MAY et al., Journal of Neuroscience, (20110000), vol. 31, pages 16507 - 16516 | - SINHA et al., Nature, (20000000), vol. 402, pages 537 - 540 | - JOHNSON-WOOD et al., Proc. Natl. Acad. Sci. USA, (19970000), vol. 94, pages 1550 - 1555 | - GAMES et al., Nature, (19950000), vol. 373, pages 523 - 527 |